Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting

NCT ID: NCT01522534

Last Updated: 2019-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the efficacity of a simple blind technic of loco regional anaesthesia of the sciatic nerve compared to the gold standard in emergency medecine : the intravenous morphine for treated the severe pain of leg, ankle or foot trauma in the prehospital setting and mountain rescue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe pain due to leg, ankle or foot trauma do not beneficiated of a simple loco regional anaesthesia technic. Loco regional anesthesia is superior to intravenous morphine for treating severe pain and specially during transportation and mobilization of the patient. The purpose of the study is to assessed a new technic of blind sciatic nerve block in the popliteal fossa in the pre hospital setting compared to the intravenous morphine. The blind technic is a modified technic of the classic sciatic nerve block with nerve stimulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injuries Pain Emergencies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blind block with mepivacaine

Blind block with mepivacaine and intravenous morphine

Group Type EXPERIMENTAL

Mepivacaine

Intervention Type DRUG

mepivacaine 1% 20 ml corresponding to 200 mg

Morphine

Intravenous Morphine and placebo blind block

Group Type ACTIVE_COMPARATOR

Morphine

Intervention Type DRUG

Morphine alone with a placebo nerve block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mepivacaine

mepivacaine 1% 20 ml corresponding to 200 mg

Intervention Type DRUG

Morphine

Morphine alone with a placebo nerve block

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

experimental group control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe pain (VAS \> or = 60mm); injuries of the leg, ankle or foot

Exclusion Criteria

* Hypersensitivity to student agents
* Local infection
* Nerve or vascular pathology in the affected limb, coagulation pathology,
* Chronic use of opoids, use of opoids within 6 hours
* Drug addiction
* Pregnancy
* Systolic blood pressure less than 90 mmHg
* Respiratory rate less than 16 per minute
* Glasgow coma scale \< 14.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Annecy Genevois

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francois Xavier AGERON, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Annecy Genevois

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier d'Albertville moutiers

Albertville, , France

Site Status

Centre Hospitalier de la Region d'Annecy

Annecy, , France

Site Status

Centre Hospitalier de Chambéry

Chambéry, , France

Site Status

Centre Hospitalier Universitaire de GRENOBLE

Grenoble, , France

Site Status

Centre medical d'Avoriaz

Morzine, , France

Site Status

Centre Hospitalier Sallanches Chamonix

Sallanches, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

chra-2009-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Contralateral Limb Block
NCT06045936 RECRUITING PHASE4